Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation

Xiaoyun Liao, Michelle K.Y.Siu, Christy W.H.Au, Esther S.Y.Wong, Hoi Yan Chan, Philip P.C.Ip, Hextan Y.S.Ngan and Annie N.Y.Cheung

Department of Pathology and 1Department of Obstetrics and Gynecology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong, China

*To whom correspondence should be addressed. Tel: +852 2855 4876; Fax: +852 2872 5197; Email: anycheun@hkucc.hku.hk

Aberrant activation of hedgehog (HH) pathway has been implicated in the development of human malignancies. This study aimed at investigating the role of HH molecules in human ovarian carcinogenesis. The expression profiles of HH molecules were examined in ovarian tumor samples and ovarian cancer cell lines and the in vitro effects of HH molecules on cell proliferation, apoptosis, migration, invasion and cell differentiation as well as related downstream target genes were assessed. Overexpression of Patched and Gli1 protein in ovarian cancers correlated with poor survival of the patients (P = 0.008; P = 0.004). Significantly elevated expression of Sonic hedgehog messenger RNA was observed in ovarian cancers compared with normal tissues and benign ovarian tumors and such differential expression was specific to histological types (P < 0.05). Ectopic Gli1 overexpression in ovarian cancer cells conferred increased cell proliferation, cell mobility, invasiveness and change in differentiation in association with increased expression of E-cadherin, vimentin, Bel-2, caspases as well as β1 integrin, membrane type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor (VEGF). Treatment with 3-keto-N-(aminoethyllaminocaproyl-dihydrocinnamomyloyl) cyclopamine induced cancer cell apoptosis, suppressed cell growth, mobility and invasiveness and induced cancer cell dedifferentiation with decreased expression of E-cadherin, cytokeratin 7, Snail, calretinin, vimentin, Bel-2, caspases, β1 integrin, MT1-MMP and VEGF. Our data suggested that abnormal HH signaling activation plays important roles in the development and progression of ovarian cancers. Gli1 expression is an independent prognostic marker. Inhibition of the HH pathway molecules might be a valid therapeutic strategy for ovarian cancers.

Introduction

Ovarian epithelial cancer is the most lethal gynecological cancer in the Western world. At the time of initial diagnosis, ~70% of patients were present with disease that has spread beyond ovaries (1). Despite advances in surgical and chemotherapeutic approaches, only 45% of patients with advanced stage of cancers can survive 5 years after initial diagnosis (1). The etiology of ovarian carcinogenesis is still among the least understood of major human malignancies (2).

It is generally accepted that ovarian epithelial cancer arises from ovarian surface epithelium (OSE) that covers the ovary. OSE is a simple, rather primitive mesothelium with both epithelial and mesenchymal characteristics. In contrast to mesothelia elsewhere, OSE retains the properties of relatively uncommitted pluripotent cells that has the ability to differentiate diversely in response to different stimuli (2). As it progresses to malignancy, OSE becomes more committed to an epithelial phenotype of the Mullerian duct in association with increased E-cadherin expression than to undergo epithelial–mesenchymal conversion (2,3). This unique characteristic distinguishes ovarian cancers from other cancers, which usually become less differentiated than the epithelium from which they arise during tumorogenesis and lose E-cadherin expression with progression (4). Moreover, ovarian cancers can metastasize by exfoliating small nodules of cohesive tumor cells from the primary tumor into the peritoneal cavity. Tumor cells can often aggregate and form spheroid-like structures that subsequently implant and invade into peritoneal tissue through E-cadherin-mediated adherens junction (3–7).

Aberrant activation of hedgehog (HH) signaling pathway has recently been reported in various human cancers (8), such as basal cell carcinoma (9), prostate cancer (10), pancreatic cancer (11,12), gastrointestinal malignancies (13–15) and ovarian cancers (16). In mammals, there are three HH ligand proteins: Sonic hedgehog (Shh), Indian HH and Desert HH. In the absence of ligands, the HH pathway is inactive. The transmembrane protein receptor Patched functions as a tumor suppressor that inhibits Smoothened (Smoo) from activating downstream signaling components and Gli-mediated transcription of target genes (17,18). Activation of the HH pathway is initiated through binding of any of the three ligands (Shh, Indian HH, Desert HH) to Patched, alleviating Patched-mediated suppression of Smoo and activating a signal cascade that leads to the translocation of active form of Gli1, a zinc finger transcriptional factor, to the nucleus and further activates targeting genes expression (17,18). Aberrant activation of HH pathway is caused through sustained increased endogenous expression of HH (ligand-dependent) or by ligand-independent mutations of Patched, Smoo and Suppressor of fused in the pathway (19,20).

In the current study, the expression and prognostic significance of Shh, Patched, Smoo and Gli1 in ovarian cancers was analyzed. The effect of Gli1 expression on cell proliferation, apoptosis, invasion propensity and differentiation was investigated with special interest in the E-cadherin-mediated morphogenic functions as an attempt to better understand the roles of HH pathway in ovarian cancer progression and differentiation.

Materials and methods

Clinical samples for immunohistochemistry

Eighty cases of formalin-fixed and paraffin-embedded primary epithelial ovarian tumor were retrieved from Department of Pathology, Queen Mary hospital, The University of Hong Kong for immunohistochemistry. Hematoxylin eosin-stained sections were reviewed to confirm the histopathological diagnosis using the standard criteria (21). Histologically, 13 of the 80 tumors were benign (five serous and eight mucinous cystadenomas), 23 were borderline tumors (five serous and eight mucinous cystadenomas), 16 were carcinomas (10 serous, 10 mucinous, 8 endometrioid and 10 clear cell adenocarcinomas). Of the 44 carcinomas, 16 were diagnosed at stage I, 5 at stage II, 10 at stage III and 11 at stage IV according to the International Federation of Gynecology and Obstetrics classification. With regard to the histological differentiation, 17 were graded as grade 1, 16 were grade 2 and 11 were grade 3. The follow-up period ranged from 5 to 111 months (median 64 months).

Clinical samples for RNA study

Snap-frozen blocks from 37 ovarian tumors including eight serous adenocarcinoma, nine endometrioid adenocarcinoma, five clear cell carcinoma and four mucinous adenocarcinoma as well as nine borderline tumors (three serous and six mucinous), two benign mucinous tumor and their corresponding normal fallopian tubes and/or contralateral ovaries were used for RNA extraction. These blocks were collected with permission of the Institution Review Board. Prior to RNA extraction, hematoxylin and eosin-stained frozen sections were examined to confirm histological diagnosis and purity of sample. Only portions of samples that consisted of at least 70% cancer were used in experiments.
Cell lines

Two human ovarian cancer cell lines SKOV3 and OVCAR3 were purchased from the American Type Culture Collection (Manassas, VA). Three ovarian cancer cell lines OVCA420, OVCA429, OVCA433 and two immortalized cell lines HOSE-6-3 and HOSE-11-12 raised from normal human ovarian surface epithelial cells were generous gifts from Prof. S.W.Tsao, Department of Anatomy, The University of Hong Kong. All five cancer cell lines were raised from serous carcinoma, among which OVCA3 and SKOV3 were from metastatic cells in the ascites. The cell lines were cultured in a 1:1 mixture of medium 199 (Invitrogen, Carlsbad, CA) and medium 105 (Sigma–Aldrich, St Louis, MO) except that OVCA420 was maintained in RPMI-1640 (Sigma–Aldrich). The medium was supplemented with 10% fetal bovine serum (FBS; Biomeda, Foster City, CA) and 1% penicillin–streptomycin. Incubation was carried out at 37°C under 5% CO2 in air.

Immunohistochemical studies were carried out on serial paraffin-embedded sections with the streptavidin–biotin–peroxidase complex method (22). Sections of 5 μm thick were deparaffinized and treated in 0.01 M citrate buffer (pH 6.0) for 15 min at 95°C in a microwave oven except that antigen retrieval for Gli1 staining was conducted by heating in a pressure cooker filled with 10 mM ethylenediaminetetraacetic acid buffer (pH 8.0) for 5 min. After cooling, they were treated with 3% hydrogen peroxide and incubated with 10% normal serum to block non-specific binding. Primary polyclonal antibodies against Shh (sc-1194), Patched (sc-9016), Smo (sc-13943) and Gli1 (sc-20687) (Santa Cruz Biotechnology, Santa Cruz, CA) were applied at 1:100 dilution and incubated at 4°C overnight. Secondary antibodies (Shh, rabbit anti-goat immunoglobulin; Patched, Smo and Gli1, goat anti-rabbit; 1:100) were applied for 30 min at room temperature; 3, 3-diaminobenzidine-hydrogen peroxide was used as chromogen. The sections were counterstained with hematoxylin, dehydrated, cleared and mounted. Known positive prostate carcinoma was used as a positive control for Patched, Smo and Gli1. Normal gastric mucosa served as positive control for Shh (23). Sections processed with replacement of primary antibody by Tris-buffered saline were used as a negative control. Immunoreactivity of these antibodies was scored according to the intensity of the staining (24): 0 (none), 1+ (weak) and 2+ (moderate) to 3+ (strong).

RNA extraction and semiquantitative reverse transcription–polymerase chain reaction

Total RNA was extracted from cells and frozen tissues using Trizol (Invitrogen) (25). First-strand complementary DNA was synthesized from 2.5 μg total RNA with oligo-dT primer and SuperScript III reverse transcriptase kit (Invitrogen) according to the manufacturer’s protocol. Primers information was summarized in Table 1. Preliminary experiments were conducted to ensure that the polymerase chain reaction (PCR) conditions were at the logarithmic phase of the reaction for each set of primers. Each PCR was optimized to ensure that a single PCR product was amplified and no product corresponding to primer–dimer pairs was present.

Quantitative real-time reverse transcription–PCR

Quantitative real-time PCR was applied to confirm the semiquantitative reverse transcription (RT)-PCR result on Gli1 expression in frozen tissues and cell lines as well as to evaluate the messenger RNA (mRNA) expression change of Gli1, E-cadherin, membrane type 1 matrix metalloproteinase (MT1-MMP) (26) and vascular endothelial growth factor (VEGF) (27) after treatment with 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay was applied. In brief, triplicate samples for each treatment were used in a 96-well format. Twenty microliters of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide was added to each well (containing 100 μl cultured medium without FBS). Four hours later, medium was aspirated and 100 μl dimethyl sulfoxide was added into each well. The 570 nm absorbance was measured with a microplate reader. Each experiment was repeated at least three times in triplicate wells. Data presented are the means and standard deviations (SDs).

Aptosis assay

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay (TUNEL) was performed according to the manufacturer’s protocol (Roche, Indianapolis, IN). In brief, cells were fixed with 4% paraformaldehyde at room temperature for 1 h and permeated with 0.1% Triton X-100, 0.1% sodium citrate (freshly prepared) on ice for 2 min. After washing with phosphate-buffered saline, each sample was incubated with 50 μl of TUNEL reaction mixture at 37°C for 30 min. TUNEL label solution (without enzyme) was used as a negative control. TUNEL-positive cells were counted under a fluorescent microscope. The counting was repeated three times and the percentage from each counting was calculated.

Matrigel invasion assay

Invasion assays were performed with 24-well BioCoat Matrigel Invasion Chambers (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions.

Table 1

| Gene | Forward primers | Reverse primers | Product size (bp) | Ref |
|------|----------------|----------------|------------------|-----|
| Shh  | ACCGAGGGGGCTGGGAGGAGAAGA | ATTTGCCCACCGCCGAGCTTGC | 211 | 15 |
| Patched | CCACGACAAACCGCCACTACAT | GGCACGATGTGCTCTTACCTTT T | 151 | Design |
| Smo  | CTTCTGCTTGTGCTTACCTTTCT | GTGACCTGGCCACCGAGCTTGC | 297 | 12 |
| Gli1 | TCTGCCCCATGCCCAGCTTTCT | TACATAGGCCCCACCGCATACCT | 480 | 14 |
| E-cadherin | TGGGTTACGTCACACTGCTTGGT | AGATGGGGCTTGCCAGACACA | 477 | 26 |
| MT1-MMP | ACGAGGATGTACATGCTTGG | TCCACCTTGTGATGATGATGTC | 129 | 27 |
| VEGF | AACCATGAACTTCTGCTCTGCT | GCCGGCCGACATCACGTAACAT | 144 | Design |

Design: The primers without a reference were designed in our laboratory.
instructions. For blockade of the pathway, cells were in serum-free medium with or without KAAD-cyclopamine after treatment with the drug for 48 h and plated onto Matrigel-coated filters. For transient transfection of Gli1, the cells were transfected with pcDNA3.1/His-Gli1 for 48 h before plated onto Matrigel-coated filters. Cells transfected with empty vector or untransfected cells were used as control. The cells that invaded through the Matrigel were stained with crystal violet solution and counted. Each experiment was done in triplicate and repeated twice. The mean values and SDs were presented. OVCAR3 cell line was not used in this experiment since, after treatment with KAAD-cyclopamine, either untreated cells, Tomatidine-treated cells or KAAD-cyclopamine-treated cells were unable to cross the Matrigel barrier despite repeated attempts, as documented in other studies (32,33).

**Wound-healing assay**

Cells were seeded into 24-well plates and allowed to grow to 90–95% confluence. Similar-sized wounds were introduced to monolayer cells using a sterile yellow pipette tip. Wounded monolayer cells were washed three times by phosphate-buffered saline to remove cell debris and then cultured with or without KAAD-cyclopamine, for ectopic overexpression of Gli1 group, cells were transfected with pcDNA3.1-HisB-hGli1 or with empty vector before wounds were introduced. The speed of wound healing was monitored and photographed every 24 h using a phase contrast microscope until complete wound healing was observed in the untreated control.

**Dual luciferase reporter assay**

SKOV3 cells (4 x 10^4 per well) were plated into 24-well culture plates and allowed to grow overnight. For ectopic overexpression of Gli1 assay, E-cadherin promoters containing different length of E-cadherin promoter (29) and pRL-TK-Luc (internal control) were cotransfected with pcDNA3.1/His-Gli1 or with empty vector using GeneJuice transfection reagent (Novagen) and lysed after 48 h. For inhibition assay, after 24 h transfection with E-cadherin promoters and pRL-TK-Luc, the cells were treated with or without KAAD-cyclopamine and lysed after 48 h. Luciferase activity was assayed using the dual luciferase reporter assay system with procedure described by the manufacturer (Promega, Madison, WI). The percentage decrease in luciferase activity of the treated cells was calculated with reference to the untreated controls. Each experiment was repeated at least twice in triplicate wells and each data point represented the mean and SD.

**Protein extraction and western blotting**

Total cell lysates from cell lines were prepared in sodium dodecyl sulfate lysis buffer containing protease inhibitors (24,34). Protein concentrations were determined using a protein assay kit (Bio-Rad) according to the manufacturer's instructions. Quantified protein lysates were separated in 7.5 or 12.5% sodium dodecyl sulfate–polyacrylamide gel and electrophoretically transferred to polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ). The membrane was blotted with 5% non-fat milk, washed and then probed with Gli1, Patched and vimentin (Santa Cruz Biotechnology), calretinin (Zymed, South San Francisco, CA), Snail (Abgent, San Diego, CA) and E-cadherin.

![Fig. 1. Representative immunostaining of Shh (A), Patched (B), Smo (C) and Gli1 (D) in benign cystadenomas (i) borderline tumors (ii) and invasive carcinomas (iii) of ovary (×20).](https://academic.oup.com/carcin/article-abstract/30/1/131/316250)
cytokeratin 7 and β-actin (Sigma-Aldrich) as well as Bcl-2, total and cleaved forms of caspases 3, 7, 9, poly(ADP-ribose) polymerase (PARP), β1-integrin (Cell signaling, Danvers, MA). After washing, the membranes were incubated with horseradish peroxidase-conjugated anti-mouse or -rabbit or -goat antibody (Santa Cruz Biotechnology) and then detected by the enhanced chemiluminescence plus system (Amersham Biosciences).

Statistical analysis

Kruskal–Wallis test and Mann–Whitney U-test were used to assess the differences of immunohistochemical staining level between or among different groups. Comparisons of the frequencies of high expression of HH molecules with different clinicopathological features were performed by Chi-square and Fisher’s exact tests. Spearman’s rank correlation was applied to determine whether there was a positive or negative correlation among staining of HH molecules. Log-rank test and Cox’s regression analysis were applied to evaluate significant predictors of patients’ survival. Cumulative survival was also analyzed by the Kaplan–Meier method. Results obtained from multiple in vitro experiments were reported as mean ± SD and were analyzed by two-tailed Student’s t-test. Differences were considered significant if P < 0.05. All analyses were performed by using SPSS 13.0 (Chicago, IL).

Results

Overexpression of Gli1 and Patched protein correlated with poor survival of ovarian cancer patients

Representative profile of immunostaining for Shh, Patched, Smo and Gli1 was shown in Figure 1. Patched and Smo expression was observed in the cytoplasm of neoplastic epithelium, whereas Shh was present in the cytoplasm, stroma and glandular lumen of tumor. While Gli1 expression was mainly detected in the cytoplasm, scattered nuclear staining was observed in the ovarian cancer cells with 3+ expression (35).

Shh protein expression was present in almost all tumors at different levels and had highest expression (3+) in cancer groups. While Patched and Smo expression was not observed in any benign mucinous tumor, they were expressed very weakly in benign serous tumors (1+). The mean expression levels of HH molecules in benign, borderline and malignant tumors in association with different histological type, grade and clinical stage were shown in supplementary Table 1 (available at Carcinogenesis Online). The immunoreactivity of Patched and Smo in borderline tumors was increased to 2+ or 3+. However, no significant difference in their protein expressions was found between borderline and malignant tumors (P > 0.05, Kruskal–Wallis and Mann–Whitney U-tests). Whereas all cancers cases had Patched expression, Patched expression was high (3+) in 34.1% (15/44) cancers. There was a positive correlation between Patched expression and Smo expression in ovarian cancers (P < 0.001, Spearman’s rank correlation). Gli1 expression was weak in benign mucinous/serous tumors and increased in borderline mucinous/serous tumors. A heterogeneous expression pattern of Gli1 in the cancer group was observed. High Gli1 expression (3+) was observed more frequently in serous carcinoma (8/16, 50%) than in non-serous carcinoma (3/28, 10.7%) (P = 0.009, Chi-square).

Fig. 2. (A) Kaplan–Meier plot on cumulative survival of patients with ovarian cancer with high and low Gli1 expression showed that high Gli1 expression was associated with poor prognosis. (B) Representative mRNA expression of Shh, Patched, Smo and Gli1 in various ovarian tissues detected by RT–PCR. (N1 and N2, normal tissues; B1, benign tumor; B2, borderline tumor; C1–C6, cancers; Ptch, Patched.) Elevated expression of Shh mRNA was observed in cancer samples, whereas sustained expression of Patched mRNA and heterogeneous expression of Gli1 mRNA was present in ovarian cancers. (C) Results of RT–PCR for Shh, Patched, Smo and Gli1 and western blotting for Patched and Gli1 in immortalized normal ovarian epithelial cell lines (HOSE 6–3, HOSE 11–12) and ovarian cancer cell lines (OVCA420, OVCA429, OVCA433, OVCAR3 and SKOV3). Sustained expression of Patched and variable expression of Gli1 mRNA and protein was observed in all seven cell lines (Ptch, Patched). (D) Mesothelial marker calretinin (Cal) and mesenchymal marker vimentin (Vim) were expressed in normal cell lines, whereas epithelial marker E-cadherin (E-Cad) and cytokeratin 7 (CK 7) were present in cancer cell lines. Snail expression was observed in all the normal and cancer cell lines.
was significantly correlated with Patched \((P < 0.001)\) and Smo \((P < 0.001)\) expression in ovarian cancers (Spearman’s rank correlation).

The expression of Patched and Gli1 was significantly correlated to patients’ survival (Log-rank and Kaplan–Meier analysis). Patients with ovarian cancers having high Gli1 expression \((3^+)(n = 11)\) had a shorter overall survival \((37.3 \pm 8.7\) months) [95% confidence interval (CI): 20.3, 54.4] than patients with cancers having lower Gli1 expression \((<3^+)(n = 32)\) \((128.2 \pm 14.0\) months) \((95\% \text{ CI}: 100.9, 155.6) (P = 0.004) (Figure 2A). Similarly, patients with high expression of Patched \((n = 15)\) also had poorer survival \((38.7 \pm 7.4\) months) \((95\% \text{ CI}: 24.2, 53.2)\) than those with lower Patched expression \((n = 28)\) \((130.3 \pm 14.3\) months) \((95\% \text{ CI}: 102.2, 158.4) (P = 0.007). The Gli1 expression was also related to disease-free survival \((P = 0.001)\). Cox’s regression analysis showed that Gli1 but not Patched was an independent prognostic factor adjusted by tumor grade, stage, histologic type and patients’ age \((P < 0.01, 95\% \text{ CI}: 1.336, 8.863). Besides Gli1, tumor grade, stage and histologic type \((\text{serous/non-serous})\) were another three independent indicators for poor prognosis \((P = 0.004, P < 0.001, P = 0.003, \text{respectively})\). No significant correlation between expression of Shh, Patched, Smo and Gli1 with tumor grade and clinical stage was found \((P > 0.05, \text{Chi-square})\).

**Elevated expression of Shh mRNA was commonly found in ovarian cancers**

In clinical samples, Shh was found to be the most frequently expressed HH ligand at mRNA level in ovarian cancers (Figure 2B). Elevated expression of Shh mRNA was observed in 57.7% \((15/26)\) of ovarian cancers, whereas its expression was weak or undetectable in normal tissues, benign and borderline tumors \((P < 0.001, \text{Chi-square})\). Elevated Shh mRNA expression was detected more frequently in endometrioid and clear cell carcinoma \((12/14, 85.7\%)\) compared with serous and mucinous carcinoma \((3/12, 25\%) (P = 0.004, \text{Chi-square})\). Sustained expression of Patched mRNA was observed in all cancer samples. A heterogeneous Gli1 mRNA was present in ovarian cancers and further confirmed by real-time PCR,
compared with their normal counterparts, elevated Gli1 mRNA expression was present in 53.8% ovarian cancers.

Expression of HH molecules and differentiation markers in ovarian cancer and normal immortalized ovarian epithelial cell lines

Consistent with RT–PCR results of clinical samples, elevated expression of Shh was observed in only one of five ovarian serous cancer cell lines, whereas Patched was consisently expressed at mRNA and protein level in immortalized ovarian epithelial cells and cancer cells with variable levels (Figure 2C). Semiquantitative RT–PCR, real-time PCR and western blotting showed significantly elevated Gli1 mRNA and protein expression in four of five ovarian cancer cell lines when compared with immortalized human ovarian epithelial cell line HOSE 6-3 and HOSE 11-12 (Figure 2C).

As shown in Figure 2D, expression of mesothelial marker calretinin and mesenchymal marker vimentin was evident in normal ovarian epithelial cell lines HOSE 6-3 and HOSE 11-12 (Figure 2C). In SKOV3 and OVCA433 cells, the expression pattern concurred with the current understanding that normal ovarian epithelial cells are of mesothelial origin with both epithelial and mesenchymal characteristics (4).

Ectopic overexpression of Gli1 increased cancer cell proliferation, invasiveness, mobility and induced differentiation change

Real-time PCR showed that Gli1 mRNA expression level was increased 12–30 folds after transfection of Gli1 into ovarian cancer cells (supplementary Figure 1A is available at Carcinogenesis Online). Introduction of Gli1 into cancer cells promoted up to 2-fold increase in cell growth (Figure 3A) and significantly increased cell invasion ability by Matrigel assay compared with empty vector control and untransfected cells (Figure 3B). After pcDNA3.1-HisB-hGli1 transfection, the migration rates of cancer cells were higher than those with empty vector control and untransfected cells (Figure 3C). Protein expression of b1 integrin, Bcl-2, total but not cleaved form of PARP and caspases 3, 7, 9, (Figure 3D) was increased with ectopic overexpression of Gli1 in association with upregulated mRNA expression of MT1-MMP and VEGF in cancer cells (Figure 4A).

Ectopic transfection of Gli1 induced significantly increased expression of mesenchymal marker vimentin in SKOV3 and OVCA433 cells as well as slightly increased Snail expression in OVCA433. Most importantly, increased rather than decreased expression of epithelial marker E-cadherin was observed (Figure 4B). Significantly increased mRNA expression of E-cadherin was demonstrated by real-time PCR in association with ectopic overexpression of Gli1 (Figure 4C). To further examine whether ectopic Gli1 expression can activate E-cadherin transcriptionally, E-cadherin promoter reporter constructs containing 37 bp (E-Cad 37), 108 bp (E-Cad 108), 368 bp (E-Cad 368) and 1359 bp (E-Cad 1359) of the 5′ flanking region of the promoter were cotransfected into SKOV3 cells. Dual luciferase assay in pcDNA3.1-HisB-hGli1-transfected cancer cells showed that E-cadherin promoter activity was upregulated at transcriptional level compared with the empty vector control (Figure 4D).

Inhibition of the HH pathway suppressed cancer cell growth, invasiveness and cell mobility, induced apoptosis and dedifferentiation in cancer cells

Gli1 mRNA expression was decreased in ovarian cancer cells after treatment with KAAD-cyclopamine (supplementary Figure 1B is available at Carcinogenesis Online). Cell proliferation was
suppressed in all three cancer cell lines compared with their controls (Tomatidine control and untreated control) (Figure 5A). In addition, obviously increased apoptosis assessed by TUNEL assay was observed in SKOV3 and OVCA433 cells after treatment (Figure 5B), whereas OVCAR3 showed no significant change. Decreased protein expression of Bcl-2, total form of caspases-3, 7, 9 and PARP as well as increased expression of cleaved caspase 7 and PARP in cancer cells after inhibition of the pathway was observed, suggesting that death receptor pathway is involved in the apoptosis induced by the blocking of HH pathway (Figure 5C).

By Matrigel invasion assay, as shown in Figure 5D, KAAD-cyclopamine-treated SKOV3 and OVCA433 cells showed much lower invasive ability compared with the Tomatidine-treated control and untreated cells as evidenced by decreased number of cells migrated through the Matrigel. Suppressive effect of KAAD-cyclopamine treatment on cancer cell mobility was also noted in wound-healing assay (Figure 6A) in association with decreased mRNA expression of MT1-MMP and VEGF (Figure 6B) and decreased protein expression of β1 integrin (Figure 5C).

In response to KAAD-cyclopamine treatment, the morphology of SKOV3 cells changed from cohesive sheets of roundish epithelioid cells to scattered small primitive cells (Figure 6C). Growth inhibition in vitro resulted in decreased E-cadherin, cytokeratin 7, Snail and calretinin protein expression (Figure 6C). In response to KAAD-cyclopamine treatment, the morphology of SKOV3 cells changed from cohesive sheets of roundish epithelioid cells to scattered small primitive cells (Figure 6C). Growth inhibition in vitro resulted in decreased E-cadherin, cytokeratin 7, Snail and calretinin protein expression (Figure 6C). Quantitative real-time PCR confirmed that after KAAD-cyclopamine blocking, significant downregulation of E-cadherin transcripts concurred with downregulation of the target gene Gli1 mRNA (Figure 6D). Furthermore, E-cadherin promoter activity was decreased by 2- to 5-folds compared with Tomatidine-treated control (Figure 6D), suggesting that
E-cadherin activity can be inactivated at transcriptional level after inhibition of the pathway. These results suggested that inhibition of the HH pathway induced dedifferentiation or regressive change of ovarian cancer cells to the more primitive pleuripotential ovarian epithelium lacking epithelial characteristics (11).

**Discussion**

HH signaling pathway controls many aspects of tissue patterning, cell proliferation and differentiation in various organs during normal development. In adult, the pathway remains active in a number of stem cells and regenerating tissues (37). Aberrant activation of the pathway was reported in a variety of human cancers but study of HH pathways in ovarian cancers has been scanty (16,38). In the current study, besides confirming the increased expression of Shh, Patched, Smo and Gli1 proteins in borderline tumors compared with benign ovarian tumors as reported by Chen et al. (16), we also documented a heterogeneous mRNA and protein expression pattern of Gli1 in the cancer group. More importantly, the association between Patched and Gli1 protein overexpression with poor survival of ovarian cancer patients was demonstrated for the first time. The predictive association of Gli1 with poor survival, in particular, was independent of other clinico-pathological parameters.

It was reported that HH signaling pathway was related to the cancer cell mobility, migration and invasiveness in several types of cancers (11,39), probably through directly participating in cell migration and angiogenesis processes (40). In our study, the correlation of Gli1 overexpression and poor survival can be explained by the cell proliferation, migration, invasion and angiogenesis-promoting effect and apoptosis-inhibiting effect of Gli1 overexpression. Such changes were associated with increased expression of VEGF, MT1-MMP and β1 integrin, which play critical roles in ovarian carcinogenesis (5,41,42). MT1-MMP is the critical determinant of matrix degradation and invasion in ovarian cancer cells, whereas integrins play important roles in the metastatic process through their participation in both cell–cell contacts and interactions with a large variety of extracellular matrix protein (43). VEGF is thought to contribute to ovarian tumor progression by stimulating angiogenesis and to promote ascites accumulation by increasing the permeability of diaphragmatic and tumor-associated vasculature (44). Overexpression of Gli1 in cancer cells also induced increased expression of Bcl-2. It is known that Bcl-2 is an anti-apoptotic gene and is an important chemotherapy-resistant factor (45). Overexpression of Bcl-2 may result in accumulation of cells in the G0 phase of cell cycle division and contribute to chemotherapy resistance (45). Thus, aberrant activation of HH may result in cancer cell resistance to apoptosis through participation of death receptor pathway.
Ectopic expression of Gli1 may also facilitate spread of the ovarian cancer cells. The increased expression of E-cadherin, in association with Gli1 overexpression, may facilitate the attachment among tumor cells to form aggregates or spheroids and tumor cells to adhere and invade the peritoneal mesothelial lining, thus contribute to their ability to colonize new sites, resulting in transcoelomic spread of ovarian cancer (5,6). Peritoneal ovarian cancer spheroids have been shown to be protected from apoptosis induced by radiation and therapeutic drugs (46). The coexisting overexpression of vimentin has been considered to be accelerating cancer cell invasiveness in breast cancer (47). Such mechanism of differentiation can contribute to more aggressive clinical behavior of ovarian cancers with Gli1 overexpression.

Inhibition of the pathway by KAAD-cyclopamine suppressed cell proliferation and induced apoptosis in vitro. Repression of cell growth may be due to induction of apoptosis as demonstrated in our study and induction of G0/G1 cell cycle arrest, which was reported recently (16). Variable sensitivity to the KAAD-cyclopamine treatment was observed. It is known that increased expression of the anti-apoptotic gene Bcl-2 causes resistance to chemotherapeutic drugs and radiation therapy, whereas decreased Bcl-2 may promote apoptotic responses to anticancer drug (45). Even though increased expression of cleaved form of caspase 7 and PARP was observed in OVCAR3 cells, OVCAR3 was quite resistant regarding effect on cancer cell apoptosis probably due to high expression of Bcl-2 or other genetic alterations despite of elevated Gli1 expression. OVCA433 cell line is the cell line most sensitive to KAAD-cyclopamine-induced apoptosis and cell growth inhibition. The nature of this sensitivity may be related to its very low expression of Bcl-2.

We also found that blockade of HH pathway inhibited ovarian cancer invasion and motility in vitro in association with decreased expression of MT1-MMP, β1 integrin and VEGF. Moreover, the inhibition induced dedifferentiation of the cancer cells to a more primitive state. After KAAD-cyclopamine treatment, cell morphology changed from tightly packed roundish appearance to scattered small primitive-like phenotype. Decreased expression of E-cadherin, cytokeratin 7, Snail, vimentin and calretinin was observed. These findings were different from mesenchymal–epithelial transition observed in pancreatic cancer cells after the same treatment (11). Instead, such changes may reflect regression to a more primitive pluripotent phenotype. Decreased expression of E-cadherin may inhibit ovarian cell invasion through disruption of cell–cell adherent junctions and preventing spheroidal morphogenesis and thus preventing them attaching to the peritoneum (5,6).

Downregulation of E-cadherin is frequently documented in epithelial–mesenchymal transitions in tumor progression (48) and dominant transcriptional repression is mainly responsible for the loss of E-cadherin expression in breast cancers (49,50). Transcriptional factor Snail is one of the repressors of E-cadherin gene expression, which in turn controls epithelial–mesenchymal transitions (51,52). Snail is also an early Gli1-responsive gene in the skin and Gli1 can directly induce Snail transcription (53). Induction of a conditional Gli1 transgene in the basal keratinocytes of mouse skin led to rapid upregulation of Snail transcripts and to cell proliferation in the interfollicular epidermis. Established Gli1-induced skin lesions exhibited molecular similarities to basal cell carcinoma, including loss of E-cadherin expression mediated by the Snail (54). However, in our current study, E-cadherin was only expressed in ovarian cancer cell lines instead of normal epithelial cell lines, whereas Snail expression was present in both cancer and normal cell lines without big difference. After treatment with KAAD-cyclopamine, decreased expression of E-cadherin was observed in association with decreased rather than increased Snail expression in SKOV3 cells. Conversely, ectopic overexpression of Gli1 in SKOV3 cells induced increased expression of E-cadherin, whereas no significant change in Snail expression was found, suggesting that Gli1-related E-cadherin expression in ovarian cancer may be regulated through Snail-independent mechanisms.

We further demonstrated that Gli1 can regulate E-cadherin expression change at transcriptional level. Since Gli1 is a sequence-specific DNA binding protein that interacts with the motif (5′-GACCACCCA-3′) and there is no binding site within the 1359 bp of E-cadherin promoter (55,56), the up- or downregulated E-cadherin transcriptional activity may be due to indirect effects of Gli1 expression possibly through other activators or repressors. After transfection of Gli1 into SKOV3, only the shorter promoter constructs E-Cad37 and E-Cad108 were associated with increased activity, whereas the longer E-Cad368 and E-Cad1359 had no response. It is possible that the transcriptional repressor binding sites are located upstream of the more proximal E-cadherin promoter elements. Increased expression of E-cadherin might also be mediated through demethylation of CpG dinucleotide of the E-cadherin promoter. Further studies are needed to explore the underlying mechanisms.

In conclusion, we showed for the first time that overexpression of Gli1 and Patched correlated with poor clinical outcome in ovarian cancer. Overexpression of Gli1 increased cancer cell aggressiveness through upregulated expression of β1-integrin, MT1-MMP, VEGF, anti-apoptotic and differentiation changes. Our findings provide a molecular basis for the role of HH pathway in ovarian cancers and suggest that inhibition of the HH pathway by KAAD-cyclopamine may be a valid therapeutic strategy for ovarian cancer.

Supplementary material

Supplementary Table 1 and Figure 1 can be found at http://carcin.oxfordjournals.org/

Funding

The University of Hong Kong Conference and Research Committee Grant (10207325).

Acknowledgements

We thank Dr Hiroshi Sasaki, Riken Center for Developmental Biology, Kobe, Japan for kindly providing us plasmids pcDNA3.1-HisB-hGli1 and Prof. S.W.Tsao, Department of Anatomy, The University of Hong Kong for pGL2-Basic-Ecad37, pGL2-Basic-Ecad108, pGL2-Basic-Ecad368 and pGL2-Basic-Ecad1359 used in the study. Some of the results of this study have been presented in the American Association for Cancer Research 99th Annual Meeting 2008 and the first author has been awarded the 2008 ITO EN, Ltd Scholar-in-Training Award by the American Association for Cancer Research. The project was performed as part of the PhD project of the first author.

Conflict of Interest Statement: None declared.

References

1. Jemal,A. et al (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43–66.
2. Auersperg,N. et al. (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev., 22, 255–288.
3. Ahmed,N. et al. (2007) Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J. Cell. Physiol., 213, 581–588.
4. Sundfeldt,K. (2003) Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Mol. Cell. Endocrinol., 202, 89–96.
5. Naora,H. et al. (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer, 5, 355–366.
6. Wu,C. et al. (2008) The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation, 76, 193–205.
7. Symowicz,J. et al. (2007) Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res., 67, 2030–2039.
18. Kalderon, D. (2002) Similarities between the Hedgehog and Wnt signaling pathway on human ovarian epithelial cancer cell invasion. Nat. Genet. 39, 773–778.

26. Mori, M. et al. (2004) Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl Acad. Sci. USA, 101, 12561–12566.

32. Chen, C.L. et al. (2004) An orderly retreat: dedifferentiation is a regulated process. Proc. Natl Acad. Sci. USA, 101, 7005–7010.

36. Katoh, M. et al. (2004) p63 expression in ovarian tumours: a marker for Brenner tumours but not transitional cell carcinomas. Br. J. Cancer, 97, 358–367.

38. Steg, A. et al. (2006) Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J. Mol. Diagn., 8, 76–83.

39. Yoo, Y.A. et al. (2008) Sonic hedgehog signaling promotes motility and invasiveness of gastric cancer cells through TGF-beta-mediated activation of the ALK5-Smad 3 pathway. Carcinogenesis, 29, 480–490.

40. Hochman, E. et al. (2006) Molecular pathways regulating pro-migratory effects of Hedgehog signaling. J. Biol. Chem., 281, 33860–33870.

41. Davidson, B. et al. (2003) Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev., 22, 103–115.

42. Sodek, K.L. et al. (2007) MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells. Br. J. Cancer, 97, 358–367.

43. Davidson, B. et al. (2003) Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin. Lab. Med., 23, 729–754, viii.

44. Byrne, A.T. et al. (2003) Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res., 9, 5721–5728.

45. Reed, J.C. (1997) Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol., 34, 9–19.

46. Makhiya, S. et al. (1999) Taxol-induced bcl-2 phosphorylation in ovarian cancer cell monolayer and spheroids. Int. J. Oncol., 14, 515–521.

47. Kokkins, M.I. et al. (2007) Vimentin and epithelial-mesenchymal transition in human breast cancer—observations in vitro and in vivo. Cells Tissues Organs, 185, 191–203.

48. Thiery, J.P. (2002) Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2, 442–454.

49. Zhou, B.P. et al. (2005) Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trepc in the regulation of metastasis. Cell Cycle, 4, 772–776.

50. Ji, X.D. et al. (1997) Transcriptional defects underlie loss of E-cadherin expression in breast cancer. Cell Growth Differ., 8, 773–778.

51. Cano, A. et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol., 2, 76–83.

52. Pellegrini, E. et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol., 2, 84–89.

53. Louroy, I.D. et al. (2002) Comparative gene expression profile analysis of GLI1 and c-MYC in an epithelial model of malignant transformation. Cancer Res., 62, 5867–5873.

54. Li, X. et al. (2006) Snail induction is an early response to GLI1 that determines the efficiency of epithelial transformation. Oncogene, 25, 609–621.

55. Kinzler, K.W. et al. (1990) The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. Mol. Cell. Biol., 10, 634–642.

56. Yoon, J.W. et al. (2002) Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem., 277, 5548–5555.

Received June 11, 2008; revised September 22, 2008; accepted September 24, 2008.